

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1 (currently amended). A method for treating a patient, to decrease the likelihood of developing or the progression of Alzheimer's disease comprising administering to the individual **in need thereof**, an effective amount of an inhibitor of memapsin 2 having an  $a K_i$  of less than or equal to  $10^{-7}$  M or which binds to crystallized enzyme characterized by the parameters in Table 2 when bound to OM-99-2 (**SEQ ID NO. 28**).

2 (original). The method of Claim 1 wherein the inhibitor is administered orally.

3 (currently amended). The method of Claim 1 wherein the inhibitor blocks cleavage of APP  **$\beta$ -amyloid precursor protein (APP)**.

4 (currently amended). The method of Claim 1 wherein the inhibitor **of memapsin 2 which binds to the crystallized enzyme characterized by the parameters in Table 2 when bound to OM-99-2 (SEQ ID NO. 28)**, is modeled using a computer program passed on the crystallization coordinates **three dimensional structure coordinates** of memapsin 2.

5 (currently amended). The method of Claim 1 wherein the inhibitor **of memapsin 2 which binds to the crystallized enzyme characterized by the parameters in Table 2 when bound to OM-99-2 (SEQ ID NO. 28)**, is modeled using a computer program based on the parameters for memapsin shown in Table 2.

6 (currently amended). The method of Claim 1 comprising creating a data base of data obtained by modeling more than one inhibitor **of memapsin 2 which binds to the crystallized enzyme characterized by the parameters in Table 2 when bound to OM-99-2 (SEQ ID NO. 28)**, based on the ~~crystallization~~ coordinates **three dimensional structure coordinates** of memapsin-2 or parameters of Table 2.